Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27053769 | 0.79 | ENPP3 (0.30) | — | |
| SCHEMBL25376794 | 0.79 | — | — | |
| SCHEMBL27296174 | 0.79 | MAPT (0.44) | MEN1NPC1LMNAGAAMAPT | |
| SCHEMBL29091630 | 0.75 | ALDH1A1 (0.40) | MEN1LMNAGAAMAPTKMT2A | |
| SCHEMBL27296163 | 0.75 | ALDH1A1 (0.37) | MEN1NPC1LMNAPOLBGAA | |
| SCHEMBL29417321 | 0.74 | NR4A2 (0.46) | CYP2A6NPC1LMNAMAPTRAB9A | |
| SCHEMBL2916780 | 0.74 | NR4A2 (0.46) | CYP2A6NPC1LMNAMAPTRAB9A | |
| SCHEMBL8139070 | 0.71 | DHODH (0.39) | CYP2A6LMNAPOLBMAPTKMT2A | |
| SCHEMBL30184670 | 0.71 | MAPT (0.51) | CYP2A6MEN1NPC1LMNAMAPT | |
| SCHEMBL18688165 | 0.71 | MAPT (0.51) | CYP2A6MEN1NPC1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238119-B1 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIËNTENZORG (NL) | 2015-11-25 | — | — | EP | disclosed |
| US-8530486-B2 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2013-09-10 | — | — | US | disclosed |
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-11-25 | — | — | US | disclosed |
| EP-2238119-A1 | QUINAZOLINES AND RELATED HETEROCYCLIC COMPOUNDS, AND THEIR THERAPEUTIC USE | Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg (NL) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009083608-A1 | QUINAZOLINES AND RELATED HETEROCYCLIC COMPOUNDS, AND THEIR THERAPEUTIC USE | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2009-07-09 | — | — | WO | disclosed |
| EP-2077263-A1 | Quinazolines and related heterocyclic compounds and their therapeutic use | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg (NL) | 2009-07-08 | — | — | EP | disclosed |
| EP-2077263-A1 | Quinazolines and related heterocyclic compounds and their therapeutic use | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg (NL) | 2009-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | RXFP3, RXFP1, NR1I3 | CYP2A6 698/4885MEN1 1483/4885NPC1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.